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CyclooxygenaseOleamide is an endocannabinoid-like, fatty acid amide with structural similarities to anandamide. The cardio-
vascular effects of anandamide are enhanced in hypertension and we have now examined how hypertension
affects responses to oleamide. Vasorelaxant responses to oleamide were signiﬁcantly (Pb0.001) enhanced in
aortic rings from spontaneously hypertensive rats (SHRs), such that the maximal relaxation to oleamide was
40.3±3.5%, compared to 15.7±3.9% in normotensive Wistar Kyoto (WKY) controls. The augmented re-
sponses to oleamide in SHR arteries were unaffected by either inhibition of nitric oxide synthase (300 μM
L-NAME) or fatty acid amide hydrolase (1 μM URB597) and independent of cannabinoid CB1 receptors or
the endothelium. The enhanced responses to oleamide were opposed by pre-treatment with capsaicin
(such that Rmax was reduced to 9.8±1.5%) and this occurred independently of TRPV1 receptor and sensory
nerve activity, as the TRPV1 antagonist capsazepine (1–5 μM) and the cation channel inhibitor ruthenium
red (10 μM) had no effect on the responses to oleamide. However, inhibition of cyclooxygenase (10 μM indo-
methacin) enhanced the responses in the WKY aortae, such that the responses were comparable to those in
the SHR. The results suggest that the cyclooxygenase pathway has a role in modulating vasorelaxation caused
by oleamide in normotensive aortae and that this is lost in hypertension, possibly as an adaptation to the in-
crease in blood pressure.
© 2012 Elsevier B.V. Open access under CC BY license.1. Introduction
The cardiovascular effects of cannabinoids are the subject of grow-
ing interest (Randall et al., 2004). The endocannabinoid, anandamide,
can have depressor effects (Ho and Gardiner, 2009; Varga et al., 1996;
Zakrzeska et al., 2010) and its production is upregulated in certain
pathophysiological states (Batkai et al., 2001; Caraceni et al., 2009;
2010). The CB1 receptor and TRPV1 receptor have both been implicat-
ed in the hypotensive effects of anandamide (Batkai et al., 2004; Lake
et al., 1997; Li et al., 2003; Wang et al., 2005). Li et al. (2003) showed
that depressor responses to the stable analogue of anandamide,
methanandamide, were enhanced in spontaneously hypertensive
rats (SHRs) compared to normotensive Wistar Kyoto (WKY) controls.
Antagonism of transient receptor potential vanilloid receptor type 1
(TRPV1) receptors reduced this hypotensive response which was
also associated with an upregulation of calcitonin gene-related pep-
tide activity in SHRs. Similarly,Wang et al. (2005) described enhanced
vasorelaxation to anandamide in mesenteric beds in a salt-sensitive
rat model of hypertension. Increased depressor effects were inhibited
by antagonism of TRPV1 and CB1 receptors, and TRPV1 expression was
upregulated in hypertension. Thus, a link between sensory nerve-: +44 115 82 30141.
M.D. Randall).
 license.mediated activity and the enhanced responses to anandamide in hy-
pertension was proposed.
Wheal and Randall (2009) examined the vascular effects of ananda-
mide in SHRs and in rats rendered hypertensive by chronic nitric oxide
(NO) synthase inhibition with L-NAME. Anandamide caused enhanced
vasorelaxation in aortic rings from SHRs compared to normotensive
WKY control preparations. The increased effects of anandamide were
attributed to endothelium-dependent mechanisms. Conversely, anan-
damide caused decreased vasorelaxant effects in perfused mesenteric
beds taken from SHRs attributed to decreased NO-dependent vasore-
laxation (Wheal and Randall, 2009). In perfused mesenteric beds,
from rats following chronic NO synthase inhibition, anandamide caused
enhanced vasorelaxation (Mendizabal et al., 2001; Wheal et al., 2007).
The enhanced responses to anandamide in L-NAME treated rats were
capsaicin-sensitive, suggesting an increase in sensory nerve activity.
This was further supported by the ﬁnding that capsaicin was shown to
cause enhanced relaxation in mesenteric beds from rats made hyper-
tensive by chronic NO inhibition.
Oleamide (cis-9 10 octadecenoamide) is a fatty acid primary amide,
which was originally derived from sleep-deprived cats (Cravatt et al.,
1995) and shares structural similarities with anandamide. In addition,
oleamide is sensitive to FAAH degradation, exerts cannabimimetic effects
in animalmodels and has been shown to be a selective agonist for canna-
binoid CB1 receptors in vitro (Boger et al., 2000; Leggett et al., 2004). To
date, oleamide has been shown to cause vasorelaxation in rat small
Fig. 1. Vasorelaxant responses to oleamide in aortic rings pre-contracted with methox-
amine from SHR and WKY rats. Mean data with bars indicating S.E.M are displayed.
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and Hiley (2006) demonstrated that the vasorelaxation was partly
endothelium-dependent, capsaicin-sensitive and involved calcium-
activated potassium channels. It was postulated that oleamide may act
via a novel cannabinoid receptor. Cannabinoid CB1 receptor and TRPV1 re-
ceptor activation have also been implicated in oleamide-induced vasore-
laxation in the rat mesenteric resistance arteries (Sudhahar et al., 2009).
In light of the enhanced cardiovascular effects of anandamide in
hypertension, the major aim of the current study was to investigate
the vasorelaxant effects of oleamide in the SHRmodel of hypertension.
2. Materials and methods
2.1. Animals
Male SHR and WKY rats (Charles River UK) (250–350 g; aged 12–
18 weeks) were used during this investigation. All rats used were
housed at the Biomedical Services Unit, University of Nottingham
with a 12 h light/dark cycle and in temperature-controlled conditions.
2.2. Methods
2.2.1. Aortic rings
Rats were stunned by a blow to the back of the head and killed by
exsanguination. These procedures are in accordance with UK legisla-
tion and have been approved by institutional ethical review. This
was followed by the removal of the abdominal aorta. Subsequently
the aorta was cleared of all connective tissue by blunt dissection and
cut into segmental rings (3 mm–5 mm). The aortic rings were placed
between twometal wires, with one being ﬁxed and the other attached
via thread to an isometric transducer and placed in 50 ml organ baths.
The organ baths were ﬁlled with modiﬁed Krebs'–Henseleit buffer
solution (NaCl 118, KCl 4.7, MgSO4 1.2, KH2PO4 4.2, NaHCO3 25,
D-glucose 10, CaCl2 2 (mM)) at 37 °C and gassed (5% CO²/95% O²).
The aortic rings were allowed to equilibrate to an optimal baseline
tension of 9.8 mN for 1 h. Tension was measured by a Leitica force
transducer coupled to an ADInstruments MacLab recording system.
Vessels were pre-contracted with the α1-adrenoceptor agonist,
methoxamine (10 μM), to achieve submaximal contraction (ca. 10 mN)
prior to the addition of oleamide (10 nM–10 μM), which was added cu-
mulatively at 5 minute intervals to construct concentration–response
curves. To investigate the role of sensory nerves, some vessels were sub-
jected to pre-treatment with 10 μM capsaicin for 1 h, which desensitises
the TRPV1 receptors and depletes the neurotransmitters (Zygmunt et
al., 1999). Capsaicin pre-treatment was followed by a 20 min wash-out
period, prior to methoxamine contraction. Concentration–responses
curves to oleamidewere also constructed in the presence of capsazepine
(1–5 μM), a TRPV1 antagonist (White et al., 2001). To further analyse
any differences in sensory nerve activity between SHR and WKY rats,
concentration–response curves to capsaicin (1 nM–10 μM) were con-
structed cumulatively. Experimentswere also carried out in the presence
of ruthenium red (10 μM), a blocker of capsaicin-activated cation chan-
nels (Harris et al., 2002).
The contribution of the endothelium to oleamide-induced responses
was assessed by denuding some vessels of endothelial cells. This was
achieved by gentle rubbing of the intimal surfacewithmetal forceps. En-
dothelial function was examined by addition of carbachol (10 μM) after
pre-contraction by methoxamine. Vessels responding to carbachol with
less than 20% relaxation of induced tone were deemed to be lacking a
functional endothelium. To inhibit nitric oxide synthase some vessels
were incubated with L-NAME (300 μM), while in other vessels indo-
methacin (10 μM) was present to inhibit cyclooxygenase (O'Sullivan et
al., 2004). Concentration–response curves to oleamide were also carried
out in the presence of niﬂumic acid (10 μM), a selective COX-2 inhibitor
(Wheal et al., 2010). In some experiments the role of cannabinoid CB1
receptors was examined by incubation of AM251 (1 μM), a cannabinoidCB1 antagonist (O'Sullivan et al., 2005). Some experiments were carried
out in the presence of URB597 (1 μM), a fatty acid amide hydrolase
(FAAH) inhibitor (Ho and Randall, 2007).
2.3. Drugs and reagents
Oleamide (cis-9 10 octadecenoamide) and AM251 (N-(piperidin-
1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-
3-carboxamide) were obtained from Tocris Co. (UK). All other drugs
used in this investigation were purchased from Sigma Chemicals Co.
(UK). Capsaicin and capsazepine were dissolved in ethanol at stock
concentrations of 10 mM. DMSO (Dimethyl sulfoxide) was used to dis-
solve stock solutions of oleamide and AM251 at 10 mM and URB597
(cyclohexylcarbamic acid 3′-carbamoyl-biphenyl-3-yl ester) at 1 mM.
All other drugs were dissolved in distilled water. L-NAME (NG-Nitro-
L-arginine methyl ester hydrochloride), indomethacin, AM251 and
capsazepine were incubated for approximately 20 min before pre-
contraction of vesselswithmethoxamine. Ruthenium red (ammoniated
ruthenium oxychloride) and niﬂumic acid were incubated for 30 min,
while URB597 was incubated for 10 min before pre-contraction.
2.4. Statistical analysis
All responses were expressed as mean data with the associated
standard error of the mean (S.E.M). The GraphPad Prism 5.0 software
(San Diego, CA) was used to plot mean data as sigmoidal concentra-
tion–response curves. The curves were used to determine potency
(pEC50 which is the negative log of the concentration causing 50% of
the maximal relaxation) and maximal response (Rmax) values. Statis-
tical signiﬁcance was determined using Student's t-test between two
data sets or one-way ANOVA when comparing multiple data-sets.
3. Results
3.1. Vascular responses to oleamide in isolated aortae from SHR andWKY
rats
Oleamide caused concentration-dependent vasorelaxation of aor-
tic segments from both SHR and WKY rats. Maximal relaxation was
signiﬁcantly (Pb0.001) greater in SHRs (Rmax=40.3±3.5%, n=6)
when compared to that in aortae from WKY rats (Rmax=15.7±3.9%,
n=6) (Fig. 1). The potency of oleamide was comparable between
SHR (pEC50=6.49±0.55, n=6) and WKY aortae (pEC50=6.08±
0.55, n=6).
3.2. Role of cannabinoid CB1 receptors in the vascular response to
oleamide in aortic segments
The vasorelaxant responses caused by oleamide (Rmax=27.6±3.5%,
pEC50=6.05±0.25, n=8) were unaffected by the presence of the
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37.3±3.5%, pEC50=6.32±0.22, n=6). Similarly, oleamide responses
(Rmax=13.1±3.2%, pEC50=5.80±0.40, n=6)were unaffected in aor-
tae from WKY rats in the presence of AM251 (1 μM) (Rmax=15.8±
1.7%, pEC50=5.90±0.21, n=4).Fig. 3. Vasorelaxant responses to oleamide in aortic rings from both SHR and WKY rats
after 1 h pre-treatment with capsaicin (10 μM). Mean data with bars indicating S.E.M
are displayed.3.3. Effects of endothelial denudation and L-NAME on the vascular
responses to oleamide
The vasorelaxant effects of oleamide in both WKY (Rmax=13.1±
3.2%, pEC50=5.80±0.40, n=6) (Fig. 2A) and SHR (Rmax=27.6±
3.5%, pEC50=6.05±0.25, n=8) (Fig. 2B) arteries were unaffected by
endothelial denudation (Rmax=10.8±2.2%, pEC50=6.20±0.44, n=6
WKY; Rmax=23.2±5.0%, pEC50=5.72±0.32, n=9 SHR). The vasore-
laxation caused by oleamide in aortae from WKY (Rmax=13.9±4.5%,
pEC50=6.05±0.71, n=5) (Fig. 2C) and SHR (Rmax=40.3±3.5%,
pEC50=6.49±0.22, n=6) (Fig. 2D) rats was unaffected by the pres-
ence of L-NAME (300 μM) (Rmax=14.6±1.7%, pEC50=5.96±0.18,
n=6 WKY; Rmax=40.8±3.7%, pEC50=6.14±0.19, n=6 SHR).3.4. The effects of capsaicin pre-treatment on vasorelaxation to oleamide
in aortae from SHR and WKY rats
Vasorelaxation to oleamidewas signiﬁcantly (Pb0.001) reduced in
the SHR arteries after pre-treatment with capsaicin for 1 h (Rmax=
9.8±1.5%, n=5, SHR) (Fig. 3), compared to the control value given
above. The potency of oleamide as a vasorelaxant was unaffected.
Pre-treatment with capsaicin caused maximal responses to oleamide
in the SHR to become comparable to responses in WKY rats such that
relaxation at 10 μM oleamide was 9.5±2.0% (n=5) compared to a
relaxation of 7.6±2.8% seen in the WKY arteries (n=6).Fig. 2. Vasorelaxation of endothelium-denuded aortae fromWKY (A) and SHR (B) rats by ole
the presence of L-NAME (300 μM). Mean data with bars indicating S.E.M are displayed.3.5. Effects of the TRPV1 antagonist capsazepine on vasorelaxant
responses to oleamide in aortae from SHR and WKY rats
Vasorelaxation to oleamide in both WKY (Rmax=13.1±3.2%,
pEC50=5.80±0.40 n=6) and SHR (Rmax=27.6±3.5%, pEC50=
6.05±0.25, n=8) arteries was unaffected by the presence of 1 μM
capsazepine (Rmax=10.0±1.5%; pEC50=5.97±0.26, n=6, WKY;
Rmax=30.4±3.8%, pEC50=5.98±0.21, n=7 SHR). Similarly, the
responses to oleamide in WKY (Rmax=6.3±3.7%, pEC50=5.64±
0.56, n=7) and SHR arteries (Rmax=43.2±7.1%, pEC50=6.13±
0.33, n=6) were unaffected by the presence of 5 μM capsazepine
(Rmax=20.3±7.5%, pEC50=5.34±0.47, n=7 WKY; Rmax=37.7±
5.5%, pEC50=6.27±0.35, n=6SHR). Vasorelaxation to oleamide in aor-
tic rings from both WKY (Rmax=6.3±3.7%, pEC50=5.64±0.56, n=7)
and SHRs (Rmax=43.2±7.1, pEC50=6.13±0.33, n=6) was unaf-
fected by the presence of 10 μM ruthenium red (Rmax=10.3±2.6%,amide. Vasorelaxant responses to oleamide in aortae fromWKY (C) and SHR (D) rats in
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n=6 SHR).
3.6. Vascular responses to capsaicin in isolated aortae from SHR and
WKY rats
The vasorelaxant responses to capsaicin were comparable in aortic
rings from both SHR and WKY rats such that at 10 μM capsaicin vaso-
relaxation in SHR aortae was 30.4±5.3% (n=9) compared to 38.0±
9.2% (n=8) (Fig. 4).
3.7. The effects of cyclooxygenase inhibitors on vasorelaxant responses to
oleamide in isolated aortae from SHR and WKY rats
Vasorelaxation to oleamide in SHR arteries (Rmax=40.3±3.5%,
pEC50=6.49±0.22, n=6) was unaffected by the presence of
10 μM indomethacin (Rmax=28.7±3.8%, pEC50=5.90±0.28, n=6)
(Fig. 5A). By contrast in aortae from WKY control rats, vasorelaxation
to oleamide was signiﬁcantly (Pb0.001) enhanced in the presence of
10 μM indomethacin such that relaxation at 10 μM oleamide was
37.3±3.6% (n=7) compared to a relaxation of 15.5±4.5% (n=6)
at this concentration in the absence of indomethacin (Fig. 5A). The en-
hanced responses to oleamide in the presence of indomethacin were
abolished by the removal of the endothelium (Fig. 5B). Vasorelaxation
to oleamide in both WKY (Rmax=13.1±6.2%, pEC50=5.65±0.57,
n=6) and SHR (Rmax=43.3±4.4%, pEC50=6.04±0.18, n=6) aortae
was unaffected by the COX-2 inhibitor niﬂumic acid (10 μM) (Rmax=
22.9±11.3%, pEC50=5.40±0.58, n=6 WKY; Rmax=41.2±6.6%,
pEC50=5.86±0.27, n=5 SHR).
3.8. Effects of the FAAH inhibitor, URB597, on vasorelaxant responses to
oleamide in aortae from SHR and WKY rats
Vasorelaxation to oleamide in WKY (Rmax=6.3±3.7%, pEC50=
5.64±0.56 n=7) (Fig. 6A) and SHR arteries (Rmax=43.2±7.1%;
pEC50=6.13±0.32, n=6) (Fig. 6B) was unaffected by the presence of
URB597 (1 μM) (Rmax=6.3±5.3%, pEC50=5.60±0.66, n=7 WKY;
Rmax=37.3±5.8%, pEC50 =5.87±0.25, n=7 SHR).
4. Discussion
The principal ﬁnding of this study is that vasorelaxation to the
endocannabinoid-like substance, oleamide is substantially enhanced
in the aorta isolated from the SHR model of hypertension and that
this may be related to alterations in prostanoid metabolism.
The aortic endothelium from SHRs is associated with an increased
CB1 receptor expression (Batkai et al., 2004). Therefore our ﬁrst
hypothesis was that the enhanced responses to oleamide might be
CB1-dependent (Leggett et al., 2004) Indeed, previous studies haveFig. 4. Vasorelaxation caused by capsaicin in isolated aortae from both SHR and WKY
rats. Mean data with bars indicating S.E.M are displayed.reported the involvement of CB1 receptors in the vascular responses
to oleamide (Hoi and Hiley, 2006; Sudhahar et al., 2009). However,
the enhanced vasorelaxation to oleamide was unaffected by the pres-
ence of AM251 and so were independent of CB1 receptor activation.
A clear ﬁnding from this study is that the enhanced effects of olea-
mide in SHR aortae are capsaicin-sensitive. This may suggest that the
enhanced effects of oleamide are due to an increase in sensory nerve
activity in the SHR. Indeed, previous studies have demonstrated in-
creased sensory nerve activity in models of hypertension (Li et al.,
2003;Wang et al., 2007). In a previous study, in the NO synthase inhi-
bition model of hypertension, anandamide induced enhanced vasore-
laxant responses in mesenteric beds were normalised by capsaicin
pre-treatment and so were ascribed to an upregulation of sensory-
nerve mediated activity (Wheal and Randall, 2009).
The enhanced responses to oleamide were sensitive to capsaicin
pre-treatment and the resulting responses were converted to a simi-
lar magnitude seen in the normotensive controls. This is clearly con-
sistent with the proposal that the enhanced responses in the SHR
arteries are due to increased sensory nerve activity. However, when
additional pharmacological approaches were used, including the
TRPV1 antagonist capsazepine, and the non-selective cation channel
blocker, ruthenium red, the enhanced responses were unaffected.
This suggests that although the mechanism underlying the enhanced
responses to oleamide is capsaicin-sensitive, it does not appear to in-
volve TRPV1 channel activation or sensory nerves. Indeed, the vasor-
elaxant responses to capsaicin alone were comparable between the
hypertensive and normotensive strains. This may suggest that there
is comparable sensory nerve activity between the strains or alterna-
tively that capsaicin is acting via mechanisms distinct from the senso-
ry nerve mediated pathway. Previous studies have demonstrated
capsaicin-induced vasorelaxation that is also insensitive to TRPV1
antagonism in the rabbit coronary artery (Yeon et al., 2001) and in
human and porcine coronary arteries (Gupta et al., 2007). In a sepa-
rate study in arteries fromWistar rats we have also shown that capsa-
icin inhibits responses to oleamide in a sensory nerve-independent
manner, which may involve inhibition of calcium inﬂux (Hopps et
al., 2012). The inhibitory effects of capsaicin might reﬂect the actions
at additional sites or inhibition of a putative, novel cannabinoid
receptor.
Enhanced vasorelaxation in SHR arteries is not unprecedented as
we have previously shown augmented responses to anandamide
(Wheal and Randall, 2009). Pomposiello et al. (2001) also reported
that vasodilatation to arachidonic acid was enhanced in the renal vas-
culature of SHR. This was ascribed to increased production of epox-
yeicoatrienoic acid from arachidonic acid.
The presence of indomethacin increased the vasorelaxant effects
of oleamide in normotensive aortae, such that they were comparable
to those from SHR. This clearly highlights the importance of the cyclo-
oxygenase pathway in regulating the responses to oleamide. In addi-
tion to our ﬁndings, other studies have shown that COX-inhibition can
increase the vasorelaxant response to endocannabinoids (Ho and
Randall, 2007) and N-oleoylethanolamine, an endocannabinoid-like
substance, (Wheal et al., 2010).
One possibility for the enhanced responses to oleamide in arteries
from normotensive rats is that oleamide or its metabolites are a sub-
strate for a COX-pathway and that this is absent in hypertension.
Therefore, metabolism of oleamide could act to limit vasorelaxation
in aortic rings from normotensive rats and so accounting for the en-
hanced effects in SHR aortae. Inhibition of the COX-pathway would
then remove the metabolic limit on vasorelaxation to oleamide in
theWKY and responses are normalised between the two strains. How-
ever, this is unlikely as oleamide would not be expected to be a sub-
strate for COX as it is monounsaturated, although there is evidence
that unsaturated fatty acids may modulate COX activity (Yuan et al.,
2009). Alternatively, it is possible that vasoconstrictor prostanoids
are being released inWKY but not SHR aortae in response to oleamide
Fig. 5. Vasorelaxation caused by oleamide (A) in aortic rings from both SHR andWKY rats in the presence of 10 μM indomethacin. Responses to oleamide inWKY preparations in the
presence of 10 μM indomethacin in endothelium denuded vessels (B). Mean data with bars indicating S.E.M are displayed.
106 J.J. Hopps et al. / European Journal of Pharmacology 684 (2012) 102–107and removal of these prostanoids enhances vasorelaxation. In any
event, it appears that COX activity in arteries from normotensive rats
truncates responses to oleamide and this is absent in the SHR.
One hypothesis to explain the augmented responses which occur
in the SHR and are uncovered in theWKY arteries following COX inhi-
bition could be that oleamide mobilises endogenous arachidonic acid.
The liberated arachidonic acid could then enter the COX pathway. It
could be that COX-dependent metabolism of arachidonic to opposing
vasoconstrictor prostanoids occurs in the WKY arteries to limit vasor-
elaxant and that this modulation is absent or impaired in SHR arteries.
In this respect we have previously shown that vasorelaxation to N-
oleoylethanolamine, which cannot be metabolised to arachidonic
acid, is also enhanced by COX inhibition and antagonism of thrombox-
ane receptors (Wheal et al., 2010). This is consistent with increased
vasoconstrictor prostanoid activity opposing vasorelaxation.
FAAH causes the hydrolysis of oleamide into oleic acid (Cravatt et
al., 1996; Deutsch et al., 1997) and has been shown to be necessary
for vasorelaxation of bovine arteries by anandamide (Pratt et al.,
1998). Coupled to this Batkai et al. (2004) reported an upregulation
of myocardial FAAH in SHR rats. However, the enhanced responses
to oleamide in the SHR aorta were not affected by FAAH inhibition.
Similarly, responses to oleamide in the normotensive controls were
also unaffected by URB597. This is in agreement with work demon-
strating FAAH-independent vascular responses to oleamide (Hoi and
Hiley, 2006; Sudhahar et al., 2009). Oleic acid, the product of oleamide
metabolism, also had no vasorelaxant effect in rat small mesenteric
arteries (Sudhahar et al., 2009). Therefore, it can be concluded that
local metabolism via FAAH is not important in mediating responses
to oleamide in either strain of rat.
Wheal and Randall (2009) demonstrated that enhanced vasore-
laxation to anandamide in aortae from SHR rats was abolished byFig. 6. Vasorelaxant responses to oleamide in the presence of the FAAH inhibitor URB597 (
displayed.the removal of the endothelium. In this study, any difference in
endothelium-dependent vasorelaxation is unlikely to account for the
enhanced effects of oleamide observed in aortic rings from hyperten-
sive rats, as endothelial denudation and inhibition of nitric oxide
synthase did not affect the vascular responses to oleamide. This is in
contrast to oleamide-induced vasorelaxation in small mesenteric
arteries, which is partly mediated by endothelium-dependent mecha-
nisms (Hoi and Hiley, 2006; Sudhahar et al., 2009). However, in nor-
motensive controls the potentiation of oleamide responses in the
presence of indomethacin was dependent on a functional endotheli-
um. This effect of indomethacin on oleamide-induced vasorelaxation
was not replicated by the presence of niﬂumic acid. At the concentra-
tions used during this investigation niﬂumic acid is 100 times more
selective at COX-2 compared to COX-1 (Johnson et al., 1995). There-
fore, it is more likely COX-1 mediates the potentiating effect of indo-
methacin on the oleamide-induced responses in WKY aortic rings.
The responses to oleamide in the WKY aortae were enhanced by
COX inhibition but this was absent in endothelium denuded vessels,
and this might imply that the COX was endothelial. However, when
the endothelium alone was removed the responses to oleamide in
aortae were not enhanced as this would predict. Therefore, the
COX-dependent mechanism which appears to modulate responses
to oleamide in the WKY but not SHR aorta cannot be localised to
the endothelium. One possibility is that the COX-dependent mecha-
nism is throughout the vascular wall (i.e. both endothelial and non-
endothelial) and that the components synergise, or at least act in par-
allel. Therefore, removing the endothelium alone does not remove
the COX-dependent mechanism, whereas global COX inhibition
removes these processes. Furthermore, the putative synergy between
endothelium-dependent modulation and no-endothelial COX is lost
on removal of the endothelium.1 μM) in both WKY (A) and SHR (B) arteries. Mean data with bars indicating S.E.M are
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In conclusion, our results demonstrate greatly enhanced vasore-
laxant effects of the endocannabinoid-like substance oleamide in aor-
tae from the SHRmodel of hypertension. The augmented responses to
oleamide were abolished by capsaicin pre-treatment but are indepen-
dent of TRPV1 receptor or sensory nerve activity. An important ﬁnding
is that vasorelaxant responses to oleamide are normalised by the pres-
ence of indomethacin in aortae. Therefore, the COX-pathway is an im-
portant component in regulating oleamide-induced vasorelaxation in
normotensive aortae and this is lost in hypertension. It is possible that
this is an adaptive change to modulate the rise in blood pressure.
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